Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. - Wikidata - wikimedia - TriplyDB

Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial.

Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial.

http://www.wikidata.org/entity/Q42686805

about

Vasoactive drugs for acute stroke Neuroprotection for ischemic stroke: past, present and future Stem cell therapy for autism Emergent properties of neural repair: elemental biology to therapeutic concepts Neuroprotection in experimental stroke with targeted neurotrophins.A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis.Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection Growth factors in ischemic stroke.Evidence for fibroblast growth factor-2 as a mediator of amphetamine-enhanced motor improvement following stroke.Treatments for stroke.Clinical trials for cytoprotection in stroke.Clinical neuroprotective drugs for treatment and prevention of stroke.Blood Pressure Reduction in the Acute Phase of an Ischemic Stroke Does Not Improve Short- or Long-Term Dependency or Mortality: A Meta-Analysis of Current Literature.Evidence, education and practice.Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.Neuroprotectants in stroke therapy.Inhibition of Endoplasmic Reticulum Stress is Involved in the Neuroprotective Effect of bFGF in the 6-OHDA-Induced Parkinson's Disease Model.Stem cells for enhancing recovery after stroke: a review.Biopharmaceutical drug targeting to the brain.Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke.Strategies to improve recovery in acute ischemic stroke patients: Iberoamerican Stroke Group Consensus.Vascular Pathology as a Potential Therapeutic Target in SCI.Tissue regeneration in stroke: cellular and trophic mechanisms.Targeted delivery of protein and gene medicines through the blood-brain barrier.Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke.Regulation of Caveolin-1 and Junction Proteins by bFGF Contributes to the Integrity of Blood-Spinal Cord Barrier and Functional Recovery.An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke.Cell Injury-Induced Release of Fibroblast Growth Factor 2: Relevance to Intracerebral Mesenchymal Stromal Cell Transplantations.SUN11602, a novel aniline compound, mimics the neuroprotective mechanisms of basic fibroblast growth factor.Regulation of GDF-15, a distant TGF-β superfamily member, in a mouse model of cerebral ischemia Trafermin for stroke recovery: is it time for another randomized clinical trial?Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats.Localized and sustained delivery of fibroblast growth factor-2 from a nanoparticle-hydrogel composite for treatment of spinal cord injury.Time for a neurorestorative therapy in stroke.Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.Enhancing Plasticity of the Central Nervous System: Drugs, Stem Cell Therapy, and Neuro-Implants.Time window of fibroblast growth factor-18-mediated neuroprotection after occlusion of the middle cerebral artery in rats.Hydrogel-delivered brain-derived neurotrophic factor promotes tissue repair and recovery after stroke.G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice.

P2860

Q24236792-5230FAA6-433C-4E7B-A08C-CF23E4BE88AD Q24645185-BFBAF565-069B-4365-8DD6-7E7162DD5BB6 Q24676771-89CDE8E8-80B7-4475-A38B-860B44DDDF61 Q28067303-2C9DCC50-78D1-4EA8-8FF2-03EC01F230E4 Q33569623-8417BFFD-4138-43EA-BAA2-57F0FD39C29B Q33863523-4D0DDDA4-99C8-4E82-91C9-BC6F96EE9688 Q33879642-188CA742-D25E-41A7-93ED-22FB99032152 Q34088803-4EFB254D-0640-427C-8CDE-E62A869E22A7 Q35216143-5D5D6BDE-4EEA-4C3E-92AD-9B5EAE07E866 Q35258422-BDAB11B7-ACDD-4771-8522-DACD9628386D Q35581150-C76E1D01-1C9A-4C24-9E1A-A697E793EEC2 Q36045223-260B0D17-00EC-4A1A-9A6B-EC8493ADE834 Q36097037-D64CDBCE-F3ED-41CC-A616-5F520D9148C2 Q36194203-B62D53B7-8F0F-4781-9E10-1D7BDBB57E5D Q36556403-CFEF45CF-5422-489E-9666-3244160271ED Q36853648-0847DD74-B14F-4FAE-B52F-5861D3FFD190 Q37123385-1D1C05C0-4229-44B4-A189-5375DE6BA5BA Q37131320-447608C7-6B3D-4CC9-B073-6F05F1373602 Q37453637-5649D5FC-478A-4711-9921-D9060BA1B37B Q37671828-109ED379-0827-406E-9D95-6853435520A7 Q37997539-36DF6373-522A-46BC-85BB-8DA1094C7F1B Q38117170-4F13A8E5-E955-48ED-A954-6BF5482D4012 Q38170038-2CDB803B-268B-40E3-B7DC-2E4AFF769F01 Q38227799-298439BD-E45E-4164-8839-4D6EB88CE3BE Q38351122-F052A234-CDB0-4A40-B7D5-252E184E75ED Q38366399-70123360-0EC3-4C8B-9D1E-2D2B27C0AFB1 Q39773588-C0654884-DC90-4F5E-85CC-AB3E8F4220FA Q40523644-FD65C6E6-B562-43A3-A123-2395107E6CCE Q41074073-83806F97-EE40-409F-B7C5-384DF5415AF5 Q41992445-CE35972A-68C8-4ABA-BA28-C2FAC62FF655 Q42587600-2356703C-999E-4738-829F-280AF7946965 Q42614796-9630AEB0-2294-416B-80DD-D97A5EE5288B Q45152011-E1DB5AE7-13F8-4E1D-A9BE-ADEC58D32F76 Q45915040-68C2D491-AA84-4FE7-ABC5-1BF5FC73B42A Q46192004-1B368653-5943-4803-BD30-B2206BDE18E9 Q47606935-41A1B562-DDAF-426E-BA83-1510FD261DAC Q47698235-22E2D1F0-3D85-4ABC-BE15-19941DD0FD5A Q48109512-416C1D55-F2A1-4326-8AE1-273E4750FA93 Q48738767-5C2B9CF4-D5FE-45C7-BE73-39D03C5DC273 Q49133551-BC73C4FF-3125-48AD-AC3B-94E0B6E1EE2C

P2860

Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial.

http://www.wikidata.org/entity/Q42686805

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Fiblast (trafermin) in acute s ...... III safety and efficacy trial.

@en

Fiblast

@nl

type

label

Fiblast (trafermin) in acute s ...... III safety and efficacy trial.

@en

Fiblast

@nl

prefLabel

Fiblast (trafermin) in acute s ...... III safety and efficacy trial.

@en

Fiblast

@nl

P1433

Q42686805-B3139271-FCED-4FD4-A113-7900AD2DB518

P1476

Q42686805-BEDD2FE5-601E-4619-833F-6DF8449B003B

P2093

Q42686805-17014D61-4DD9-4C91-99BB-959BA9BB0804

Q42686805-185BA01A-3E9E-43AE-B9B8-99473CDB80EB

Q42686805-2FDAD2C9-7AD5-4B64-AE4C-224F1D0747F6

Q42686805-375B1E7E-FD66-4B51-A1A7-5F594E3502D1

Q42686805-472A33C9-B3D1-4546-815D-EC255BA09EAF

Q42686805-77659E6C-C676-4971-A975-DED8B8E2BBEC

Q42686805-90773025-CBC9-422A-A31D-E27C927F5690

Q42686805-9BC3F7EF-66B7-4E69-B454-80A893F74AC6

Q42686805-C4D604FB-381D-4788-90B7-6476354EAD02

P304

Q42686805-7ADCBA18-C619-4B06-80A8-FBD0DD54141B

P31

Q42686805-E1C1F6D8-547E-4CC1-A887-709AE9B50034

P356

Q42686805-A1303AE5-F929-4FE1-BF9A-30817C5B163D

P433

Q42686805-AEEA0BEA-41CF-4DE1-8A43-B64E8F6D867C

P478

Q42686805-F5213819-118B-431A-96F3-9FD92B549298

P50

Q42686805-396ADBCC-F3B2-44F2-8F25-E752A391A3C7

Q42686805-489D943C-DA91-4A14-85A2-9EA88820FAA3

P577

Q42686805-D2AFACF8-6416-4C90-B4D1-3C703F951B50

P698

Q42686805-F716101E-8882-42C4-8F0F-B718D728D6E7

P921

Q42686805-98849F4E-DB8C-4665-BF61-CA29E16E15DF

Q42686805-AEBE9111-3A6C-4717-810A-894F3F4AE6A9

P356

P1433

Cerebrovascular Diseases

P1476

Fiblast (trafermin) in acute s ...... III safety and efficacy trial.

@en

P2093

Allan Pallay

http://www.w3.org/2001/XMLSchema#string

Angel Chamorro

http://www.w3.org/2001/XMLSchema#string

Anne Desmet

http://www.w3.org/2001/XMLSchema#string

Cesare Fieschi

http://www.w3.org/2001/XMLSchema#string

Eliseo O Salinas

http://www.w3.org/2001/XMLSchema#string

European-Australian Fiblast (Trafermin) in Acute Stroke Group

http://www.w3.org/2001/XMLSchema#string

Jean-Marc M Orgogozo

http://www.w3.org/2001/XMLSchema#string

Julien Bogousslavsky

http://www.w3.org/2001/XMLSchema#string

Stephen J Victor

http://www.w3.org/2001/XMLSchema#string

P304

239-251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000065683

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey A. Donnan

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12403958

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial